Research programme: autoimmune disease therapeutics - Janssen Biotech/Nodality
Latest Information Update: 18 Jan 2014
At a glance
- Originator Janssen Biotech; Nodality
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 08 Jan 2014 Early research in Rheumatoid arthritis in USA (unspecified route)
- 08 Jan 2014 Early research in Inflammatory bowel disease in USA (unspecified route)